Stay updated on Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial
Sign up to get notified when there's something new on the Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial page.

Latest updates to the Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe update changes the displayed ClinicalTrials.gov page revision number from v3.5.2 to v3.5.3, reflecting a tooling/interface release rather than a modification to the trial record data.SummaryDifference0.1%

- Check15 days agoChange DetectedRevision: v3.5.2 is now listed, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check23 days agoChange DetectedA new version entry was added to the Record History, reflecting updates to the study record such as status, design, eligibility, and contacts/locations.SummaryDifference0.1%

- Check44 days agoChange DetectedRevision history shows the addition of v3.5.0 and the removal of v3.4.3.SummaryDifference0.1%

- Check51 days agoChange DetectedRecord History shows the addition of Revision: v3.4.3 and the deletion of Revision: v3.4.2.SummaryDifference0.1%

- Check80 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-notice block along with the prior Revision: v3.4.1 entry.SummaryDifference0.8%

Stay in the know with updates to Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Study of DPX-Survivac Combo with Pembrolizumab in Clinical Trial page.